Infection, Human Immunodeficiency VirusPhase 1NCT02373930
Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects
A Phase 1 study testing DTG 50 mg, RPV 25 mg and DTG/RPV 50 mg/25 mg: Product Code AS in people with Infection, Human Immunodeficiency Virus, run by ViiV Healthcare at 1 site in United States.
Trial summary
Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration of a combination of antiretroviral drugs to reduce the patient's HIV levels. Dolutegravir (DTG), a HIV-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Infection, Human Immunodeficiency Virus
- What is being tested?
- DTG 50 mg, RPV 25 mg and DTG/RPV 50 mg/25 mg: Product Code AS
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2015to Sep 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac evaluation (history, electrocardiogram [ECG]).
- A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the medical monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight >=50 kilograms (kg) (110 pounds [lbs]) for men and >=45 kg (99 lbs) for women and body mass index (BMI) within the range 18.5-31.0 kg/square meter (m^2) (inclusive).
- Male or Female- Female: Female subject of non-reproductive potential : is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: Pre-menopausal females with one of the following: documented tubal ligation, documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, hysterectomy, documented bilateral oophorectomy.
- Postmenopausal defined as 12 months of spontaneous amenorrhea; in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels). Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
Show all 25Show fewer
- Reproductive potential and agrees to follow one of the options listed below in the GlaxoSmithKline (GSK) modified list of highly effective methods for avoiding pregnancy in females of reproductive potential (FRP) requirements from 30 days prior to the first dose of study medication and until at least five terminal half-lives (10 days) after the last dose of study medication and completion of the follow-up visit.
- GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP)
- This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long term and persistent basis.
- Intrauterine device that meets the standard operating procedure (SOP) effectiveness criteria including a <1% rate of failure per year, as stated in the product label.
- Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject.
- Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository).
- These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
- Male:
- Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until [at least five half-lives of study medication OR for a cycle of spermatogenesis following five terminal half-lives] after the last dose of study medication.
- Vasectomy with documentation of azoospermia.
- Male condom plus partner use of one of the contraceptive options below:
- Contraceptive subdermal implant that meets the SOP effectiveness criteria including a <1% rate of failure per year, as stated in the product label.
- Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a <1% rate of failure per year, as stated in the product label.
- Oral Contraceptive, either combined or progestrogen alone.
- Injectable progestrogen.
- Contraceptive vaginal ring.
- Percutaneous contraceptive patches.
- These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
- Capable of giving signed informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
Who cannot join
- Alanine aminotransferase (ALT) and bilirubin >1.5x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
Show all 18Show fewer
- A positive pre-study drug/alcohol screen.
- A positive test for HIV antibody.
- Where participation in the study would result in donation of blood or blood product in excess of 500 mL within 56 days.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination):
- Heart Rate for males: <45 and >100 beats per minute (bpm), females: <50 and >100 bpm PR Interval for males: <120 and >220 milliseconds (msec) QRS Interval for males: <70 and >120 msec QT duration corrected for heart rate (QTc) interval (Fridericia's) for males: >450 msec Note: A heart rate from 100 to 110 bpm can be rechecked by ECG or vitals within 30 minutes to verify eligibility.
- Evidence of previous myocardial infarction (does not include ST segment changes associated with repolarization).
- Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular block (AV block) (2nd degree or higher), Wolf Parkinson White [WPW] syndrome).
- Sinus Pauses >3 seconds. Any significant arrhythmia which, in the opinion of the principal investigator OR GSK medical monitor, will interfere with the safety for the individual subject.
- Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats).
- Employment with Janssen and GSK or with the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator.
Trial locations and contacts
1 site in 1 country.
United States1 site
GSK Investigational Site
Overland Park, Kansas, 66211
About this study
Official title: A Phase I, 2-part Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Fasted and Fed Healthy Subjects
Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration of a combination of antiretroviral drugs to reduce the patient's HIV levels. Dolutegravir (DTG), a HIV-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are approved for the treatment of HIV infection. This study is aimed to evaluate the relative bioavailability and food effect of single doses of several experimental fixed dose combination (FDC) tablets of Dolutegravir 50 milligrams (mg) and Rilpivirine 25 mg (DTG/RPV 50 mg/25 mg) relative to co-administration of a single dose of the reference single entity products (DTG 50 mg and RPV 25 mg) in healthy adult subjects. This is a 2-part study. Part 1 will be conducted as a randomized, open label, 3-way, crossover design in 24 subjects. Part 1 will evaluate the relative bioavailability of up to 4 test formulations relative to the reference single entity products administered in fed state. Part 2 will be conducted as a randomized, open-label, 3-way crossover design in 3 distinct cohorts each with 12 subjects. Part 2 will evaluate the relative bioavailability of up to 3 most promising FDC formulation selected from Part 1 (DTG/RPV FDC-1, DTG/RPV FDC-2, DTG/RPV FDC-3) administered in fasted and fed state. Subjects will also receive the reference treatment from Part 1 co-administered under fasted conditions. This study will consist of a screening visit, three treatment periods each with a single dose of study drug separated by a washout of at least 9 days and a follow-up visit. The total duration of participation of a subject in this study will be approximately 10 weeks.
- Conditions
- Infection, Human Immunodeficiency Virus
- Being tested
- DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS, DTG/RPV 50 mg/25 mg: Product Code AM, DTG/RPV 50 mg/25 mg: Product Code AQ
- Keywords
- Dolutegravir, safety, Rilpivirine, fixed dose combination, relative bioavailability
- Medical subject headings
- Infections, Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DTG 50 mgDrug
Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
RPV 25 mgDrug
Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
DTG/RPV 50 mg/25 mg: Product Code ASDrug
DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
DTG/RPV 50 mg/25 mg: Product Code AMDrug
DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
DTG/RPV 50 mg/25 mg: Product Code AQDrug
DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
DTG/RPV 50 mg/25 mg: Product Code AKDrug
DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
DTG/RPV 50 mg/25 mg: Product Code ARDrug
DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
| Study group | Role | What they receive |
|---|---|---|
| Part 1 Cohort 1- Sequence 1 | Experimental | Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM |
| Part 1 Cohort 1- Sequence 2 | Experimental | Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ |
| Part 1 Cohort 1- Sequence 3 | Experimental | Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AK |
| Part 1 Cohort 1- Sequence 4 | Experimental | Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ |
| Part 1 Cohort 1- Sequence 5 | Experimental | Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AK |
| Part 1 Cohort 1- Sequence 6 | Experimental | Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK |
| Part 2 Cohort 2- Sequence 1 | Experimental | Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 2- Sequence 2 | Experimental | Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 2- Sequence 3 | Experimental | Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 3- Sequence 4 | Experimental | Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 3- Sequence 5 | Experimental | Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 3- Sequence 6 | Experimental | Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 4- Sequence 7 | Experimental | Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 4- Sequence 8 | Experimental | Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
| Part 2 Cohort 4- Sequence 9 | Experimental | Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. Receives: Drug: DTG 50 mg; Drug: RPV 25 mg; Drug: DTG/RPV 50 mg/25 mg: Product Code AS; Drug: DTG/RPV 50 mg/25 mg: Product Code AM; Drug: DTG/RPV 50 mg/25 mg: Product Code AQ; Drug: DTG/RPV 50 mg/25 mg: Product Code AK; Drug: DTG/RPV 50 mg/25 mg: Product Code AR |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite of pharmacokinetic (PK) parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1)
PK parameters will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-Infinity]), maximum observed concentration (Cmax) and apparent oral clearance (CL/F)
Measured: Part 1: Pre-dose and 0.25 hours (h), 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fasted state (Part 2)
PK parameters will include AUC (0-Infinity), Cmax and CL/F
Measured: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Composite of PK parameters of DTG and RPV to evaluate the effect of food on the bioavailability of selected FDC formulation(s) of DTG and RPV (Part 2)
PK parameters will include AUC (0-Infinity), Cmax and CL/F
Measured: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Secondary outcomes (6)
Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1)
PK parameters will include area under the curve from time of dose administration to time of last quantifiable post-dose sample (AUC[0-t]), observed concentration at 24 h post-dose (C24), terminal elimination phase half-life (t1/2), lag time for absorption (tlag) and time to maximum observed concentration (tmax).
Measured: Part 1: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fasted state (Part 2)
PK parameters will include AUC (0-t), C24, t1/2, tlag and tmax.
Measured: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Composite of PK parameters of DTG and RPV to evaluate the effect of food on the bioavailability of selected FDC formulation(s) of DTG and RPV (Part 2)
PK parameters will include AUC (0-t), C24, t1/2, tlag and tmax.
Measured: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Change from baseline in vital signs
Vital signs will include systolic and diastolic blood pressure and pulse rate
Measured: Part 1 and 2: Baseline (Day 1) and up to Day 35
Number of subjects with adverse events (AEs)
AEs and serious adverse events (SAEs) will be collected from the start of study treatment until the follow-up contact.
Measured: Part 1 and 2: Up to Day 35
Composite of clinical laboratory assessments
Clinical laboratory tests will include hematology, clinical chemistry, urinalysis parameters
Measured: Part 1 and 2: Up to Day 35
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2015 (estimated)
- Study startFeb 2015
- Primary completionSep 2015
- Study completionSep 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infection, Human Immunodeficiency VirusStudies of the same condition, open and under way.
- More trials run by ViiV HealthcareThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 63 participants (actual)
Sponsor and investigators
- Lead sponsor
- ViiV Healthcare
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Janssen Pharmaceuticals, GlaxoSmithKline
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, ViiV Healthcare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02373930
- Sponsor's protocol ID
- 201674
- Status last verified
- Jun 2016
- First submitted
- 23 Feb 2015
- Last updated
- 27 Jun 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, 2-part Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Fasted and Fed Healthy Subjects
- ClinicalTrials.gov ID
- NCT02373930
- Acronym / sponsor ID
- 201674
- Conditions
- Infection, Human Immunodeficiency Virus
- Keywords
- Dolutegravir, safety, Rilpivirine, fixed dose combination, relative bioavailability
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 63 participants (actual)
- Lead sponsor
- ViiV HealthcareIndustry (pharma, biotech, devices)
- Collaborators
- Janssen Pharmaceuticals, GlaxoSmithKline
- Study start
- Feb 2015
- Primary completion
- Sep 2015 (actual)
- Study completion
- Sep 2015 (actual)
- First posted
- 27 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration of a combination of antiretroviral drugs to reduce the patient's HIV levels. Dolutegravir (DTG), a HIV-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are approved for the treatment of HIV infection. This study is aimed to evaluate the relative bioavailability and food effect of single doses of several experimental fixed dose combination (FDC) tablets of Dolutegravir 50 milligrams (mg) and Rilpivirine 25 mg (DTG/RPV 50 mg/25 mg) relative to co-administration of a single dose of the reference single entity products (DTG 50 mg and RPV 25 mg) in healthy adult subjects. This is a 2-part study. Part 1 will be conducted as a randomized, open label, 3-way, crossover design in 24 subjects. Part 1 will evaluate the relative bioavailability of up to 4 test formulations relative to the reference single entity products administered in fed state. Part 2 will be conducted as a randomized, open-label, 3-way crossover design in 3 distinct cohorts each with 12 subjects. Part 2 will evaluate the relative bioavailability of up to 3 most promising FDC formulation selected from Part 1 (DTG/RPV FDC-1, DTG/RPV FDC-2, DTG/RPV FDC-3) administered in fasted and fed state. Subjects will also receive the reference treatment from Part 1 co-administered under fasted conditions. This study will consist of a screening visit, three treatment periods each with a single dose of study drug separated by a washout of at least 9 days and a follow-up visit. The total duration of participation of a subject in this study will be approximately 10 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 15
| Arm | Type | Receives |
|---|---|---|
| Part 1 Cohort 1- Sequence 1 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AMEach subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. |
| Part 1 Cohort 1- Sequence 2 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AQEach subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. |
| Part 1 Cohort 1- Sequence 3 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AKEach subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. |
| Part 1 Cohort 1- Sequence 4 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQEach subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. |
| Part 1 Cohort 1- Sequence 5 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AKEach subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. |
| Part 1 Cohort 1- Sequence 6 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AKEach subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state. |
| Part 2 Cohort 2- Sequence 1 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 2- Sequence 2 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 2- Sequence 3 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 3- Sequence 4 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 3- Sequence 5 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 3- Sequence 6 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 4- Sequence 7 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 4- Sequence 8 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
| Part 2 Cohort 4- Sequence 9 | Experimental | Drug: DTG 50 mg, Drug: RPV 25 mg, Drug: DTG/RPV 50 mg/25 mg: Product Code AS, Drug: DTG/RPV 50 mg/25 mg: Product Code AM, Drug: DTG/RPV 50 mg/25 mg: Product Code AQ, Drug: DTG/RPV 50 mg/25 mg: Product Code AK, Drug: DTG/RPV 50 mg/25 mg: Product Code AREach subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac evaluation (history, electrocardiogram [ECG]).
- A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the medical monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight >=50 kilograms (kg) (110 pounds [lbs]) for men and >=45 kg (99 lbs) for women and body mass index (BMI) within the range 18.5-31.0 kg/square meter (m^2) (inclusive).
- Male or Female- Female: Female subject of non-reproductive potential : is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: Pre-menopausal females with one of the following: documented tubal ligation, documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, hysterectomy, documented bilateral oophorectomy.
Key exclusion criteria (18 listed)
- Alanine aminotransferase (ALT) and bilirubin >1.5x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DTG 50 mgDolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally | Drug | Part 1 Cohort 1- Sequence 1, Part 1 Cohort 1- Sequence 2, Part 1 Cohort 1- Sequence 3, Part 1 Cohort 1- Sequence 4, Part 1 Cohort 1- Sequence 5, Part 1 Cohort 1- Sequence 6, Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
| RPV 25 mgRilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally | Drug | Part 1 Cohort 1- Sequence 1, Part 1 Cohort 1- Sequence 2, Part 1 Cohort 1- Sequence 3, Part 1 Cohort 1- Sequence 4, Part 1 Cohort 1- Sequence 5, Part 1 Cohort 1- Sequence 6, Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
| DTG/RPV 50 mg/25 mg: Product Code ASDTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally | Drug | Part 1 Cohort 1- Sequence 1, Part 1 Cohort 1- Sequence 2, Part 1 Cohort 1- Sequence 3, Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
| DTG/RPV 50 mg/25 mg: Product Code AMDTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally | Drug | Part 1 Cohort 1- Sequence 1, Part 1 Cohort 1- Sequence 4, Part 1 Cohort 1- Sequence 5, Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
| DTG/RPV 50 mg/25 mg: Product Code AQDTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally | Drug | Part 1 Cohort 1- Sequence 2, Part 1 Cohort 1- Sequence 4, Part 1 Cohort 1- Sequence 6, Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
| DTG/RPV 50 mg/25 mg: Product Code AKDTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally | Drug | Part 1 Cohort 1- Sequence 3, Part 1 Cohort 1- Sequence 5, Part 1 Cohort 1- Sequence 6, Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
| DTG/RPV 50 mg/25 mg: Product Code ARDTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally | Drug | Part 2 Cohort 2- Sequence 1, Part 2 Cohort 2- Sequence 2, Part 2 Cohort 2- Sequence 3, Part 2 Cohort 3- Sequence 4, Part 2 Cohort 3- Sequence 5, Part 2 Cohort 3- Sequence 6, Part 2 Cohort 4- Sequence 7, Part 2 Cohort 4- Sequence 8, Part 2 Cohort 4- Sequence 9 |
Primary outcome
Composite of pharmacokinetic (PK) parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1)
Time frame: Part 1: Pre-dose and 0.25 hours (h), 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
PK parameters will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-Infinity]), maximum observed concentration (Cmax) and apparent oral clearance (CL/F)
Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fasted state (Part 2)
Time frame: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
PK parameters will include AUC (0-Infinity), Cmax and CL/F
Composite of PK parameters of DTG and RPV to evaluate the effect of food on the bioavailability of selected FDC formulation(s) of DTG and RPV (Part 2)
Time frame: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
PK parameters will include AUC (0-Infinity), Cmax and CL/F
6 secondary outcomes
Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1)
Time frame: Part 1: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fasted state (Part 2)
Time frame: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Composite of PK parameters of DTG and RPV to evaluate the effect of food on the bioavailability of selected FDC formulation(s) of DTG and RPV (Part 2)
Time frame: Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.
Change from baseline in vital signs
Time frame: Part 1 and 2: Baseline (Day 1) and up to Day 35
Number of subjects with adverse events (AEs)
Time frame: Part 1 and 2: Up to Day 35
Composite of clinical laboratory assessments
Time frame: Part 1 and 2: Up to Day 35
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2016.
Related trials for Infection, Human Immunodeficiency Virus
RecruitingPhase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Human Immunodeficiency Virus (HIV) Infection
RecruitingPhase 2/3
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Recruiting
Screening With Portable X-rays for Rapid Recognition of TB
Tuberculosis (TB), Tuberculosis Infection, Latent
Not yet recruitingObservational study
Innate-like and NK Signatures in Chronic-Treated HIV Infection INSTINCT-HIV
Human Immunodeficiency Virus Infection (HIV)
RecruitingPhase 2
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Acquired Immunodeficiency Syndrome, BK Virus Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
ViiV Healthcare
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DTG 50 mg, RPV 25 mg and DTG/RPV 50 mg/25 mg: Product Code AS in people with Infection, Human Immunodeficiency Virus, run by ViiV Healthcare at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite of pharmacokinetic (PK) parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1) (time frame: Part 1: Pre-dose and 0.25 hours (h), 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2016; AzTrials last refreshed its copy on 4 Nov 2026.